These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 36279879)

  • 1. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial.
    Jabbour E; Short NJ; Jain N; Thompson PA; Kadia TM; Ferrajoli A; Huang X; Yilmaz M; Alvarado Y; Patel KP; Garcia-Manero G; Macaron W; Garris R; Konopleva M; Ravandi F; Kantarjian H
    Lancet Haematol; 2022 Dec; 9(12):e878-e885. PubMed ID: 36279879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.
    Jabbour E; Short NJ; Senapati J; Jain N; Huang X; Daver N; DiNardo CD; Pemmaraju N; Wierda W; Garcia-Manero G; Montalban Bravo G; Sasaki K; Kadia TM; Khoury J; Wang SA; Haddad FG; Jacob J; Garris R; Ravandi F; Kantarjian HM
    Lancet Haematol; 2023 Jun; 10(6):e433-e444. PubMed ID: 37187201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial.
    Jabbour E; Richard-Carpentier G; Sasaki Y; Konopleva M; Patel K; Roberts K; Gu Z; Wang F; Huang X; Sasaki K; Short NJ; Jain N; Ravandi F; Daver NG; Kadia TM; Alvarado Y; DiNardo CD; Issa GC; Pemmaraju N; Garcia-Manero G; Verstovsek S; Wang S; Khoury JD; Jorgensen J; Champlin R; Khouri I; Kebriaei P; Schroeder H; Khouri M; Mullighan CG; Takahashi K; O'Brien SM; Kantarjian H
    Lancet Haematol; 2020 Jul; 7(7):e523-e533. PubMed ID: 32589978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.
    Jabbour E; Short NJ; Jain N; Huang X; Montalban-Bravo G; Banerjee P; Rezvani K; Jiang X; Kim KH; Kanagal-Shamanna R; Khoury JD; Patel K; Kadia TM; Daver N; Chien K; Alvarado Y; Garcia-Manero G; Issa GC; Haddad FG; Kwari M; Thankachan J; Delumpa R; Macaron W; Garris R; Konopleva M; Ravandi F; Kantarjian H
    Lancet Haematol; 2023 Jan; 10(1):e24-e34. PubMed ID: 36402146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.
    Kantarjian H; Ravandi F; Short NJ; Huang X; Jain N; Sasaki K; Daver N; Pemmaraju N; Khoury JD; Jorgensen J; Alvarado Y; Konopleva M; Garcia-Manero G; Kadia T; Yilmaz M; Bortakhur G; Burger J; Kornblau S; Wierda W; DiNardo C; Ferrajoli A; Jacob J; Garris R; O'Brien S; Jabbour E
    Lancet Oncol; 2018 Feb; 19(2):240-248. PubMed ID: 29352703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.
    Jabbour E; Short NJ; Ravandi F; Huang X; Daver N; DiNardo CD; Konopleva M; Pemmaraju N; Wierda W; Garcia-Manero G; Sasaki K; Cortes J; Garris R; Khoury JD; Jorgensen J; Jain N; Alvarez J; O'Brien S; Kantarjian H
    Lancet Haematol; 2018 Dec; 5(12):e618-e627. PubMed ID: 30501869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.
    Jabbour E; Kantarjian H; Ravandi F; Thomas D; Huang X; Faderl S; Pemmaraju N; Daver N; Garcia-Manero G; Sasaki K; Cortes J; Garris R; Yin CC; Khoury JD; Jorgensen J; Estrov Z; Bohannan Z; Konopleva M; Kadia T; Jain N; DiNardo C; Wierda W; Jeanis V; O'Brien S
    Lancet Oncol; 2015 Nov; 16(15):1547-1555. PubMed ID: 26432046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial.
    Jabbour E; Ravandi F; Kebriaei P; Huang X; Short NJ; Thomas D; Sasaki K; Rytting M; Jain N; Konopleva M; Garcia-Manero G; Champlin R; Marin D; Kadia T; Cortes J; Estrov Z; Takahashi K; Patel Y; Khouri MR; Jacob J; Garris R; O'Brien S; Kantarjian H
    JAMA Oncol; 2018 Feb; 4(2):230-234. PubMed ID: 28859185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
    Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
    Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.
    Advani AS; Moseley A; O'Dwyer KM; Wood BL; Fang M; Wieduwilt MJ; Aldoss I; Park JH; Klisovic RB; Baer MR; Stock W; Bhave RR; Othus M; Harvey RC; Willman CL; Litzow MR; Stone RM; Sharon E; Erba HP
    J Clin Oncol; 2022 May; 40(14):1574-1582. PubMed ID: 35157496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial.
    Hunger SP; Tran TH; Saha V; Devidas M; Valsecchi MG; Gastier-Foster JM; Cazzaniga G; Reshmi SC; Borowitz MJ; Moorman AV; Heerema NA; Carroll AJ; Martin-Regueira P; Loh ML; Raetz EA; Schultz KR; Slayton WB; Cario G; Schrappe M; Silverman LB; Biondi A
    Lancet Haematol; 2023 Jul; 10(7):e510-e520. PubMed ID: 37407142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
    Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
    Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.
    Pan J; Tang K; Luo Y; Seery S; Tan Y; Deng B; Liu F; Xu X; Ling Z; Song W; Xu J; Duan J; Wang Z; Li C; Wang K; Zhang Y; Yu X; Zheng Q; Zhao L; Zhang J; Chang AH; Feng X
    Lancet Oncol; 2023 Nov; 24(11):1229-1241. PubMed ID: 37863088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
    Kantarjian HM; O'Brien S; Smith TL; Cortes J; Giles FJ; Beran M; Pierce S; Huh Y; Andreeff M; Koller C; Ha CS; Keating MJ; Murphy S; Freireich EJ
    J Clin Oncol; 2000 Feb; 18(3):547-61. PubMed ID: 10653870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results.
    Kantarjian H; Short NJ; Jain N; Sasaki K; Huang X; Haddad FG; Khouri I; DiNardo CD; Pemmaraju N; Wierda W; Garcia-Manero G; Kebriaei P; Garris R; Loghavi S; Jorgensen J; Kwari M; O'Brien S; Ravandi F; Jabbour E
    Am J Hematol; 2023 Mar; 98(3):493-501. PubMed ID: 36600670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial.
    Lu J; Qiu H; Wang Y; Zhou X; Dai H; Lu X; Yang X; Gu B; Hong M; Miao M; Lu R; Wang J; Wu Q; Xue M; Wang Y; Deng A; Shen Y; Liu Y; Dou X; Lei Y; Wu D; Zhu Y; Chen S
    J Hematol Oncol; 2024 Sep; 17(1):79. PubMed ID: 39218935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
    Ravandi F; Assi R; Daver N; Benton CB; Kadia T; Thompson PA; Borthakur G; Alvarado Y; Jabbour EJ; Konopleva M; Takahashi K; Kornblau S; DiNardo CD; Estrov Z; Flores W; Basu S; Allison J; Sharma P; Pierce S; Pike A; Cortes JE; Garcia-Manero G; Kantarjian HM
    Lancet Haematol; 2019 Sep; 6(9):e480-e488. PubMed ID: 31400961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ravandi F; O'Brien SM; Cortes JE; Thomas DM; Garris R; Faderl S; Burger JA; Rytting ME; Ferrajoli A; Wierda WG; Verstovsek S; Champlin R; Kebriaei P; McCue DA; Huang X; Jabbour E; Garcia-Manero G; Estrov Z; Kantarjian HM
    Cancer; 2015 Dec; 121(23):4158-64. PubMed ID: 26308885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
    Locatelli F; Zugmaier G; Rizzari C; Morris JD; Gruhn B; Klingebiel T; Parasole R; Linderkamp C; Flotho C; Petit A; Micalizzi C; Mergen N; Mohammad A; Kormany WN; Eckert C; Möricke A; Sartor M; Hrusak O; Peters C; Saha V; Vinti L; von Stackelberg A
    JAMA; 2021 Mar; 325(9):843-854. PubMed ID: 33651091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
    DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
    Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.